In Thursday’s Wall Street session, Neumora Therapeutics Inc (NASDAQ:NMRA) shares traded at $0.82, up 5.04% from the previous session.
NMRA stock price is now 7.16% away from the 50-day moving average and -84.47% away from the 200-day moving average. The market capitalization of the company currently stands at $132.89M.
With the price target maintained at $1, BofA Securities recently Downgraded its rating from Buy to Underperform for Neumora Therapeutics Inc (NASDAQ: NMRA). , while ‘Stifel’ rates the stock as ‘Hold’
In other news, Henry Gosebruch, Officer bought 15,000 shares of the company’s stock on Mar 12 ’25. The stock was bought for $21,450 at an average price of $1.43. An SEC document containing details of the transaction can be found on the SEC’s website. On Feb 18 ’25, BERNS PAUL L sold 13,871 shares of the business’s stock. A total of $23,468 was realized by selling the stock at an average price of $1.69. This leaves the insider owning 7,405,004 shares of the company worth $6.07 million. A total of 59.69% of the company’s stock is owned by insiders.
During the past 12 months, Neumora Therapeutics Inc has had a low of $0.61 and a high of $17.19. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 8.98, and a quick ratio of 8.98. The fifty day moving average price for NMRA is $0.76678 and a two-hundred day moving average price translates $5.28919 for the stock.
The latest earnings results from Neumora Therapeutics Inc (NASDAQ: NMRA) was released for 2025-03-31. The company reported revenue of $70.94 million for the quarter, compared to $60.07 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 18.08 percent.
